Unnamed: 0 float64 0 336 ⌀ | Ticker stringclasses 2
values | Year stringclasses 8
values | Text stringlengths 4 2.95k | Embedding stringlengths 9 34.6k |
|---|---|---|---|---|
161 | LLY | 2017 | •We recognized a provisional tax expense of $1.91 billion, or $1.81 per share, due to the 2017 Tax Act. Refer to “Results of Operations - Executive Overview - Other Matters - Tax Matters” for further discussion of the 2017 Tax Act. | [-0.010151541791856289, -0.022090695798397064, 0.0036143665201961994, -0.056003108620643616, -0.005963052622973919, -0.007933339104056358, -0.0146401422098279, -0.01730198599398136, -0.009394743479788303, -0.0021823206916451454, 0.016819199547171593, 0.025926882401108742, -0.0012819910189136863, 0.004775661043822765, 0... |
162 | LLY | 2017 | •We recognized acquired IPR&D charges of $30.0 million (pretax), or $0.02 per share, related to upfront fees paid in connection with a collaboration agreement with AstraZeneca to co-develop MEDI1814, a potential disease-modifying treatment for Alzheimer's disease. | [0.003813780378550291, 0.006298867519944906, 0.013187529519200325, -0.045513544231653214, 0.0026192818768322468, 0.01830349490046501, -0.010622919537127018, 0.0052120559848845005, -0.009933721274137497, 0.009575868956744671, 0.013180902227759361, 0.031199440360069275, 0.011166324838995934, 0.005917821079492569, -0.0018... |
163 | LLY | 2017 | •We recognized charges of $382.5 million (pretax), or $0.29 per share, related to integration and severance costs related to the acquisition of Novartis Animal Health (Novartis AH), other global severance costs, and asset impairments primarily related to the closure of an animal health manufacturing facility in Ireland... | [-0.005401816219091415, -0.007174031343311071, 0.014963915571570396, -0.021030722185969353, -0.007193686440587044, 0.015789421275258064, -0.007927468977868557, 0.006495938170701265, -0.01348324865102768, -0.0016804923070594668, 0.006561454385519028, 0.03451396897435188, 0.012264645658433437, -0.0022128119599074125, 0.0... |
164 | LLY | 2017 | •We recognized charges of $203.9 million (pretax), or $0.19 per share, related to the impact of the Venezuelan financial crisis, including the significant deterioration of the bolívar. | [-0.022566957399249077, -0.009017745964229107, 0.011599777266383171, -0.0363808274269104, -0.0008811182924546301, -0.01183861494064331, -0.007752550300210714, -0.013465295545756817, -0.01061215065419674, 0.0030484111048281193, 0.009508331306278706, 0.04219039902091026, 0.004944590851664543, 0.0028483036439865828, -0.00... |
165 | LLY | 2017 | Our long-term success depends to a great extent on our ability to continue to discover and develop innovative pharmaceutical products and acquire or collaborate on molecules currently in development by other biotechnology or pharmaceutical companies. We currently have approximately 40 potential new drugs in human testi... | [-0.0005073743523098528, -0.014145678840577602, 0.007480381987988949, -0.022230802103877068, -0.01419826503843069, 0.021034466102719307, -0.010648698545992374, 0.03128876909613609, -0.020653216168284416, 0.020403431728482246, 0.0024912697263062, 0.0158547293394804, 0.006182161159813404, -0.012489214539527893, -0.019483... |
166 | LLY | 2017 | The following new molecular entities (NMEs) have been approved by regulatory authorities in at least one of the major geographies for use in the diseases described. The first quarter in which each NME initially was approved in any major geography for any indication is shown in parentheses: | [-0.006300901994109154, -0.0070906151086091995, 0.0068049742840230465, -0.03602435812354088, -0.020727448165416718, 0.027179570868611336, -0.018254132941365242, 0.008737251162528992, -0.02459872141480446, -0.00021318052313290536, 0.007796316407620907, 0.007440105080604553, 0.003385684685781598, 0.021695265546441078, -0... |
167 | LLY | 2017 | Abemaciclib (Verzenio™) (Q3 2017)—a small molecule cell-cycle inhibitor, selective for cyclin-dependent kinases 4 and 6 for the treatment of metastatic breast cancer. | [-0.04487067088484764, -0.019293606281280518, -0.0033959352876991034, -0.021574944257736206, -0.00030411058105528355, 0.045913565903902054, -0.028236452490091324, -0.005566466134041548, -0.017416389659047127, -0.0016784133622422814, 0.03569317236542702, 0.004738666117191315, 0.014783074147999287, -0.01894162781536579, ... |
168 | LLY | 2017 | Baricitinib (Olumiant®) (Q1 2017)—a Janus tyrosine kinase inhibitor for the treatment of moderate-to-severe active rheumatoid arthritis (in collaboration with Incyte Corporation). | [-0.0256879311054945, -0.010303758084774017, -0.013889933936297894, -0.004638640210032463, 0.005934730637818575, 0.039837732911109924, -0.028923286125063896, 0.00024179885804187506, -0.018788442015647888, 0.003069688333198428, 0.024557506665587425, -0.00802991446107626, 0.00046410763752646744, -0.00911486241966486, -0.... |
169 | LLY | 2017 | Olaratumab* (Lartruvo™) (Q4 2016)—a human lgG1 monoclonal antibody for the treatment of advanced soft tissue sarcoma. | [-0.018696220591664314, -0.008009908720850945, -0.021050941199064255, -0.022569283843040466, 0.01478455401957035, 0.017216477543115616, -0.02756180614233017, -0.0015818765386939049, -0.037057891488075256, 0.013703699223697186, 0.023469997569918633, -0.00414006132632494, 0.0045292978174984455, -0.00397921958938241, -0.0... |
170 | LLY | 2017 | The following NME has been submitted for regulatory review in at least one of the major geographies for potential use in the disease described. The first quarter in which the NME initially was submitted in any major geography for any indication is shown in parentheses: | [-0.002312910044565797, -0.010120024904608727, 0.019852615892887115, -0.028242550790309906, -0.005253728944808245, 0.034361325204372406, -0.024394938722252846, 0.015537410974502563, -0.026532500982284546, -0.001143930247053504, -0.0025333461817353964, 0.008082659915089607, 0.005450785625725985, 0.02407430298626423, -0.... |
171 | LLY | 2017 | Galcanezumab* (Q3 2017)—a once-monthly subcutaneously injected calcitonin gene-related peptide (CGRP) antibody for the treatment of migraine prevention. Refer to Item 3, "Legal Proceedings—Other Patent Litigation" for discussion of the lawsuit filed by Teva Pharmaceuticals International GMBH. | [-0.027111850678920746, 0.005200390238314867, 0.021723732352256775, -0.031801752746105194, -0.0027467545587569475, 0.009076804853975773, -0.027638806030154228, -0.011731342412531376, -0.013898446224629879, -0.008431284688413143, 0.023818379268050194, 0.01513679139316082, 0.010848692618310452, -0.015176312997937202, 0.0... |
172 | LLY | 2017 | The following NMEs and diagnostic agent are currently in Phase III clinical trial testing for potential use in the diseases described. The first quarter in which each NME and diagnostic agent initially entered Phase III for any indication is shown in parentheses: | [-0.011107422411441803, -0.011504356749355793, 0.019550679251551628, -0.02307599037885666, -0.013502481393516064, 0.0419808104634285, -0.02111150324344635, 0.01138998568058014, -0.030166979879140854, -0.002092312788590789, 0.012822984717786312, 0.02454262785613537, 0.017814934253692627, 0.015056578442454338, -0.0021579... |
173 | LLY | 2017 | Flortaucipir** (Q3 2015)—a positron emission tomography (PET) tracer intended to image tau (or neurofibrillary) tangles in the brain, which are an indicator of Alzheimer's disease. | [-0.026889478787779808, -0.004320815671235323, 0.019754188135266304, -0.01638474501669407, -0.006256593856960535, 0.02071877382695675, -0.027986200526356697, 0.01409880816936493, -0.023797519505023956, -0.006732279900461435, 0.013847751542925835, 0.03102530539035797, -0.008932327851653099, 0.030734607949852943, -8.9242... |
174 | LLY | 2017 | Lanabecestat (Q2 2016)—an oral beta-secretase cleaving enzyme (BACE) inhibitor for the treatment of early and mild Alzheimer's disease (in collaboration with AstraZeneca). | [-0.027220234274864197, -0.006234914064407349, 0.020591886714100838, -0.012316456064581871, -0.006968433503061533, 0.03512890636920929, -0.031981442123651505, 0.0210853461176157, -0.03334178775548935, -1.513404549768893e-05, 0.013736816123127937, 0.020031746476888657, 0.01385684683918953, 0.006008190102875233, 0.017964... |
175 | LLY | 2017 | Lasmiditan (Q2 2015)—an oral 5-HT1F agonist for the acute treatment of migraine. | [-0.010203065350651741, 0.01867082715034485, 0.008572140708565712, -0.017196470871567726, -0.016896380111575127, 0.012825592420995235, -0.042117003351449966, -0.013373583555221558, -0.00336622865870595, -0.002873689401894808, 0.032331451773643494, 0.025246715173125267, -0.0063149407505989075, 0.007665346376597881, -0.0... |
176 | LLY | 2017 | Nasal glucagon* (Q3 2013)—a glucagon nasal powder formulation for the treatment of severe hypoglycemia in patients with diabetes treated with insulin. | [-0.028885310515761375, -0.007437574211508036, 0.02145428955554962, -0.015569759532809258, 0.012830634601414204, 0.004220086149871349, -0.022974569350481033, -0.025451576337218285, -0.007332727313041687, 0.0046460265293717384, 0.032554950565099716, 0.01056332141160965, -0.008879219181835651, -0.013020670041441917, -0.0... |
177 | LLY | 2017 | Solanezumab* (Q2 2009)—an anti-amyloid beta monoclonal antibody for the treatment of preclinical Alzheimer’s disease. | [-0.01752433367073536, 0.0020671533420681953, 0.0031167545821517706, -0.014075872488319874, -0.017511513084173203, 0.03579220175743103, -0.021229185163974762, 0.00423686346039176, -0.026921067386865616, 0.012063202448189259, 0.022113734856247902, 0.021690689027309418, 0.007762241177260876, 0.009101885370910168, -0.0103... |
178 | LLY | 2017 | Tanezumab* (Q3 2008)—an anti-nerve growth factor monoclonal antibody for the treatment of osteoarthritis pain, chronic low back pain, and cancer pain (in collaboration with Pfizer Inc. (Pfizer)). | [-0.028119591996073723, -0.008919795975089073, -0.0038942364044487476, -0.021410126239061356, -0.004505673889070749, 0.003449554555118084, -0.036385443061590195, -0.013745902106165886, -0.02683786116540432, -0.0037994144950062037, 0.029296690598130226, 0.0044435495510697365, 0.016610177233815193, -0.009253307245671749,... |
179 | LLY | 2017 | Ultra-rapid Lispro* (Q3 2017)—an ultra-rapid insulin for the treatment of type 1 and type 2 diabetes. | [-0.02037900686264038, -0.007512490265071392, 0.008199568837881088, -0.008795901201665401, -0.003594198264181614, 0.018927067518234253, -0.01219240203499794, -0.008037521503865719, -0.017526984214782715, -0.02460518851876259, 0.014519394375383854, 0.021156832575798035, -0.021416107192635536, -0.02369772642850876, -2.49... |
180 | LLY | 2017 | *Biologic molecule subject to the U.S. Biologics Price Competition and Innovation Act | [-0.02431727945804596, -0.013593589887022972, -0.006598208099603653, -0.0015934993280097842, -0.0034720669500529766, 0.018756847828626633, -0.008097218349575996, 0.004621948581188917, -0.03510503098368645, -0.008821099996566772, -0.0019730564672499895, 0.012318790890276432, 0.021677996963262558, -0.017168153077363968, ... |
181 | LLY | 2017 | (1) The FDA's fast track program is designed to expedite the development and review of new therapies to treat serious conditions and address unmet medical needs. | [-0.008558712899684906, -0.0008622952736914158, -0.02025364339351654, -0.004526432603597641, 0.005798050202429295, 0.009257114492356777, -0.019476179033517838, -0.00729368394240737, -0.013236685656011105, 0.019528888165950775, 0.024325456470251083, 0.004276062361896038, -0.0030225631780922413, -0.010588030330836773, -0... |
182 | LLY | 2017 | (2) Continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory Phase III trial. | [-0.0007377235451713204, -0.019574478268623352, -0.009633613750338554, -0.014428016729652882, -0.004506354685872793, 0.041683781892061234, -0.036434903740882874, 0.0020915502682328224, -0.0021315570920705795, -0.00116739550139755, 0.002851677592843771, 0.011093057692050934, 0.0012882157461717725, -0.0088462820276618, -... |
183 | LLY | 2017 | (3) As part of a conditional marketing authorization, results from an ongoing Phase III study will need to be provided. This study is fully enrolled. Until availability of the full data, the Committee for Medicinal Products for Human Use will review the benefits and risks of Lartruvo annually to determine whether the c... | [0.0012164436047896743, -0.008269157260656357, 0.004543383605778217, -0.028742633759975433, -0.006394637748599052, 0.020619714632630348, -0.018878139555454254, -0.0015803795540705323, -0.035788699984550476, 0.006421226542443037, 0.029912546277046204, -0.008242568001151085, -0.0036792431492358446, -0.013573648408055305,... |
184 | LLY | 2017 | There are many difficulties and uncertainties inherent in human pharmaceutical research and development and the introduction of new products. There is a high rate of failure inherent in new drug discovery and development. To bring a drug from the discovery phase to market can take over a decade and often costs in exces... | [0.012534328736364841, -0.015640122815966606, 0.0005663986667059362, -0.021485552191734314, -0.006057932041585445, 0.0032316597644239664, 0.009343534708023071, 0.007689290679991245, -0.04493265971541405, 0.008558913134038448, 0.007159671280533075, 0.012050478719174862, -0.0071792867965996265, 0.006561397109180689, -0.0... |
185 | LLY | 2017 | We manage research and development spending across our portfolio of molecules, and a delay in, or termination of, any one project will not necessarily cause a significant change in our total research and development spending. Due to the risks and uncertainties involved in the research and development process, we cannot... | [-0.007667657919228077, -0.025770746171474457, 0.0013127056881785393, -0.03085603192448616, -0.0020741743501275778, 0.003322320757433772, 0.00984612014144659, 0.01113730575889349, -0.025227786973118782, 0.019149281084537506, 0.015269100666046143, 0.024366995319724083, 0.002340688370168209, 0.010806232690811157, -0.0145... |
186 | LLY | 2017 | We are reviewing strategic alternatives for Elanco Animal Health (our animal health segment), including an initial public offering, merger, sale, or retention of the business, and will provide an update no later than the middle of 2018. | [-0.018229147419333458, -0.022690018638968468, 0.0007138838991522789, -0.021751563996076584, -0.01663506217300892, 0.015799451619386673, -0.03198457136750221, 0.0033842194825410843, -0.01601799577474594, 0.010245861485600471, 0.0069934106431901455, 0.015143820084631443, 0.011839947663247585, -0.011659969575703144, 0.01... |
187 | LLY | 2017 | We depend on patents or other forms of intellectual-property protection for most of our revenue, cash flows, and earnings. We lost patent exclusivity for the schizophrenia and bipolar mania indications for Zyprexa® in Japan in December 2015 and April 2016, respectively. Generic versions of Zyprexa launched in Japan in ... | [-0.0006312125478871167, -0.011234164237976074, 0.03882228210568428, -0.04098500683903694, -0.005506943445652723, 0.02549881674349308, -0.0034977435134351254, 0.006514880806207657, 0.0038214849773794413, -0.028489254415035248, 0.0018957235151901841, 0.013777370564639568, 0.006531568709760904, -0.002581588225439191, -0.... |
188 | LLY | 2017 | We lost our patent exclusivity for Strattera® in the U.S. in May 2017, and generic versions of Strattera were approved in the same month. As described in Note 15 to the consolidated financial statements, following the settlement related to the compound patent challenge for Effient®, generic products launched in the U.S... | [-0.03191494941711426, -0.004661472514271736, 0.0008480319520458579, -0.029971836134791374, 0.0006708560977131128, 0.03234083577990532, 0.0022126189433038235, -0.001736822654493153, -0.0141607616096735, -0.014639885164797306, 0.017221828922629356, 0.024994276463985443, -0.008950293064117432, 0.005037451162934303, 0.003... |
189 | LLY | 2017 | Our compound patent protection for Cialis® (tadalafil) and Adcirca® (tadalafil) expired in major European markets and the U.S. in November 2017. However, Cialis is protected by a unit dose patent in the U.S., where we expect exclusivity to end in late September 2018 at the earliest. We expect that the entry of generic ... | [-0.014170206151902676, -0.005974750965833664, 0.03566344827413559, -0.028472596779465675, -0.000375693867681548, 0.04179682210087776, -0.012233699671924114, -0.0034334990195930004, -0.027415119111537933, -0.013641467317938805, 0.028922025114297867, 0.03328412026166916, 0.013575375080108643, 0.0052774762734770775, 0.00... |
190 | LLY | 2017 | revenue for the affected products, which will, in the aggregate, have a material adverse effect on our consolidated results of operations and cash flows. | [-0.03324278071522713, -0.035355452448129654, 0.00011374706809874624, -0.004839420784264803, 0.007712528575211763, 0.0019329047063365579, -0.023150311782956123, -0.0167995672672987, -0.0036494513042271137, -0.015475965104997158, 0.010709724389016628, 0.027948370203375816, -0.008202515542507172, -0.0055903103202581406, ... |
191 | LLY | 2017 | Additionally, as described in Note 15 to the consolidated financial statements, the Alimta® vitamin regimen patents, which provide us with patent protection for Alimta through June 2021 in Japan and major European countries, and through May 2022 in the U.S., have been challenged in each of these jurisdictions. Our vita... | [-0.0029874544125050306, -0.014574279077351093, 0.016428442671895027, -0.031929805874824524, -0.014410675503313541, 0.04629958048462868, -0.004028717987239361, -0.02501758746802807, -0.015255956910550594, -0.016632946208119392, 0.009563944302499294, 0.005589760839939117, 0.009516227059066296, -0.012283840216696262, -0.... |
192 | LLY | 2017 | The compound patent for Humalog® (insulin lispro) has expired in major markets. Thus far, the loss of compound patent protection for Humalog has not resulted in a rapid and severe decline in revenue. Global regulators have different legal pathways to approve similar versions of insulin lispro. A similar version of insu... | [-0.015282615087926388, -0.010854506865143776, 0.023196114227175713, -0.007309365551918745, 0.009115130640566349, 0.014924117363989353, -0.00040268729208037257, 0.001624856609851122, -0.0232226699590683, -0.036991629749536514, 0.02120446227490902, -0.0038040566723793745, -0.015136560425162315, -0.010104318149387836, 0.... |
193 | LLY | 2017 | As a global company with substantial operations outside the U.S., we face foreign currency risk exposure from fluctuating currency exchange rates, primarily the U.S. dollar against the euro, Japanese yen, and British pound. While we manage a portion of these exposures through hedging and other risk management technique... | [-0.012287204153835773, -0.02402404323220253, -0.0026270297821611166, -0.014872636646032333, -0.003855750197544694, 0.0066043720580637455, -0.008261865004897118, 0.0008967418689280748, -0.0010823298944160342, -0.016933303326368332, -0.013106350786983967, 0.022987309843301773, 0.0067259641364216805, -0.00295180873945355... |
194 | LLY | 2017 | The impact of the Venezuelan financial crisis, including the significant deterioration of the bolívar, resulted in a charge of $203.9 million in 2016. See Note 17 to the consolidated financial statements for additional information related to the charge. As of December 31, 2017, our Venezuelan subsidiaries represented a... | [-0.03815882280468941, -0.01351513247936964, 0.018182797357439995, -0.03560083732008934, -0.017431223765015602, 0.0044006588868796825, -0.01992328278720379, -0.0006394964875653386, 0.0020025470294058323, -0.016402756795287132, 0.006342222914099693, 0.03277914226055145, 0.0038600536063313484, 0.015611626207828522, -0.00... |
195 | LLY | 2017 | In the U.S., public concern over access to and affordability of pharmaceuticals continues to drive the regulatory and legislative debate. These policy and political issues increase the risk that taxes, fees, rebates, or other federal and state measures may be enacted. Key health policy proposals affecting biopharmaceut... | [-0.013151422142982483, -0.00927865132689476, -0.0023829869460314512, -0.021610192954540253, 0.0021430219057947397, 0.014744523912668228, -0.004929283633828163, 0.0011340018827468157, -0.032528605312108994, -0.013578026555478573, 0.01814403012394905, 0.005412546917796135, 0.002949571469798684, 0.0005249237292446196, 0.... |
196 | LLY | 2017 | In the private sector, consolidation and integration among healthcare providers is also a major factor in the competitive marketplace for human pharmaceuticals. Health plans, pharmaceutical benefit managers, wholesalers, and other supply chain stakeholders have been consolidating into fewer, larger entities, thus enhan... | [0.015571043826639652, -0.005034094210714102, 0.005601363722234964, -0.009687744081020355, -0.026481645181775093, 0.031060563400387764, 0.002980713499709964, 0.003281332552433014, -0.02970183454453945, -0.023315804079174995, 0.028098532930016518, 0.013655235059559345, 0.006263744551688433, 0.017310218885540962, -0.0092... |
197 | LLY | 2017 | The main coverage expansion provisions of the Affordable Care Act (ACA) are currently in effect through both state-based exchanges and the expansion of Medicaid. A trend has been the prevalence of benefit designs containing high out-of-pocket costs for patients, particularly for pharmaceuticals. In addition to the cove... | [-0.021190468221902847, -0.002024482237175107, 0.024666717275977135, -0.025079604238271713, -0.027184000238776207, 0.008930363692343235, -0.01831357181072235, 0.0018246977124363184, -0.0248798206448555, 0.018100468441843987, 0.023747708648443222, 0.0234147347509861, 0.006226614583283663, 0.01091488916426897, -0.0110081... |
198 | LLY | 2017 | International operations also are generally subject to extensive price and market regulations. Cost-containment measures exist in a number of countries, including additional price controls and mechanisms to limit reimbursement for our products. Such policies are expected to increase in impact and reach, given the press... | [0.0018714286852627993, -0.021342530846595764, -0.007089994382113218, -0.0294679943472147, 0.004168257117271423, 0.019443072378635406, 0.002897004596889019, 0.014021700248122215, -0.020392801612615585, -0.014127225615084171, -0.006819585338234901, 0.003192146308720112, 0.001535066170617938, -0.007650598417967558, -0.00... |
199 | LLY | 2017 | We are subject to income taxes in the U.S. and numerous foreign jurisdictions. Changes in the relevant tax laws, regulations, administrative practices, principles, and interpretations could adversely affect our future effective tax rates. The U.S. recently enacted tax reform legislation significantly revising U.S. tax ... | [-0.014634164050221443, -0.04333232715725899, 0.007215719670057297, -0.05151732265949249, -0.005970865488052368, 0.0029490056913346052, -0.013569860719144344, 0.006683568470180035, 0.0027573679108172655, -0.010592347010970116, 0.011637644842267036, 0.0001466979883844033, 0.019144780933856964, 0.011523611843585968, -0.0... |
200 | LLY | 2017 | In December 2017, the President of the U.S. signed into law the Tax Cuts and Jobs Act (2017 Tax Act). The 2017 Tax Act includes significant changes to the U.S. corporate income tax system, such as the reduction in the corporate income tax rate, transition to a territorial tax system, changes to business related exclusi... | [-0.030277736485004425, -0.02684485726058483, 0.012666142545640469, -0.0446142852306366, -0.0034361679572612047, -0.025582188740372658, -0.016756663098931313, -0.013757824897766113, -0.010561695322394371, -0.012442545033991337, 0.02692377381026745, 0.016217397525906563, 0.002219534246250987, 0.015270396135747433, -0.00... |
201 | LLY | 2017 | •Our acquisition of Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine, and rabies vaccine portfolio and other related assets (BIVIVP), completed on January 3, 2017, in an all-cash transaction for $882.1 million. | [-0.014097931794822216, -0.004550090990960598, -0.0029381827916949987, -0.028169138357043266, -0.032899629324674606, 0.00963470060378313, -0.012200389988720417, -0.022249342873692513, 0.006314002443104982, 0.005642513278871775, 0.010048951953649521, 0.014512184076011181, 0.0069220177829265594, -0.011699278838932514, 0.... |
202 | LLY | 2017 | •Our acquisition of CoLucid, completed on March 1, 2017, for a cash purchase price of $831.8 million, net of cash acquired. | [0.0046454137191176414, 0.014214900322258472, 0.023223791271448135, -0.02427286095917225, -0.001850625267252326, -0.002604644512757659, -0.03097379580140114, -0.015277083963155746, -0.004779825918376446, 0.015578691847622395, 0.01441160123795271, 0.029872272163629532, -0.0016260587144643068, -0.00779590243473649, 0.007... |
203 | LLY | 2017 | Numbers may not add due to rounding. | [-0.008122851140797138, -0.008246813900768757, 0.028420191258192062, -0.0178376492112875, -0.017668016254901886, -0.003810236928984523, -0.03303945064544678, -0.02540592849254608, -0.01646753028035164, -0.02672385238111019, 0.008971019648015499, 0.025014465674757957, -0.021517399698495865, 0.003350268118083477, -0.0113... |
204 | LLY | 2017 | (1) U.S. revenue includes revenue in Puerto Rico. | [-0.002270389348268509, -0.026054497808218002, 0.00866758357733488, -0.010976782999932766, 0.016377851366996765, -0.022458096966147423, 0.003209916641935706, -0.0053557902574539185, 0.014864258468151093, -0.0334542840719223, 0.012102275155484676, 0.01859002560377121, 0.003389413235709071, -0.010905630886554718, -0.0095... |
205 | LLY | 2017 | Numbers may not add due to rounding. | [-0.008122851140797138, -0.008246813900768757, 0.028420191258192062, -0.0178376492112875, -0.017668016254901886, -0.003810236928984523, -0.03303945064544678, -0.02540592849254608, -0.01646753028035164, -0.02672385238111019, 0.008971019648015499, 0.025014465674757957, -0.021517399698495865, 0.003350268118083477, -0.0113... |
206 | LLY | 2017 | In the U.S., the revenue increase in 2017 was driven by increased volume for new pharmaceutical products, including Trulicity®, Taltz®, Basaglar®, Lartruvo, and Jardiance®, and higher realized prices for several pharmaceutical products, primarily Forteo® and Cialis, as well as increased volume for companion animal prod... | [0.003916190471500158, -0.021575992926955223, 0.025458598509430885, -0.016726097092032433, 0.001080646994523704, 0.009928181767463684, -0.01939958520233631, -0.014401908963918686, -0.031033962965011597, -0.018768159672617912, 0.01777399703860283, 0.033747754991054535, -0.0050043947994709015, -0.0011041575344279408, 0.0... |
207 | LLY | 2017 | Outside the U.S., the revenue increase in 2017 was due to increased volume for several new pharmaceutical products, primarily driven by Trulicity and Cyramza®. The increase in revenue was partially offset by competitive pressure and the loss of exclusivity for Alimta in several countries and lower volume from the loss ... | [0.011066780425608158, -0.022367917001247406, 0.02202940359711647, -0.018670309334993362, 0.01000567153096199, 0.01191957388073206, -0.009530451148748398, -0.01035720482468605, -0.02395632490515709, -0.023279298096895218, 0.03228896111249924, 0.02153465338051319, 0.0040003159083426, -0.016248637810349464, -0.0007824051... |
208 | LLY | 2017 | Numbers may not add due to rounding. | [-0.008122851140797138, -0.008246813900768757, 0.028420191258192062, -0.0178376492112875, -0.017668016254901886, -0.003810236928984523, -0.03303945064544678, -0.02540592849254608, -0.01646753028035164, -0.02672385238111019, 0.008971019648015499, 0.025014465674757957, -0.021517399698495865, 0.003350268118083477, -0.0113... |
209 | LLY | 2017 | (1) U.S. revenue includes revenue in Puerto Rico. | [-0.002270389348268509, -0.026054497808218002, 0.00866758357733488, -0.010976782999932766, 0.016377851366996765, -0.022458096966147423, 0.003209916641935706, -0.0053557902574539185, 0.014864258468151093, -0.0334542840719223, 0.012102275155484676, 0.01859002560377121, 0.003389413235709071, -0.010905630886554718, -0.0095... |
210 | LLY | 2017 | (2) Trajenta revenue includes Jentadueto®.[DATA_TABLE_REMOVED] | [-0.01831241324543953, -0.01708155684173107, 0.01787477545440197, 0.0015872924122959375, 0.0197894424200058, 0.01363515853881836, -0.03498368710279465, -0.030333781614899635, -0.018380794674158096, -0.02471286989748478, 0.020404871553182602, 0.029376449063420296, -0.002632665913552046, -0.006944084074348211, 0.00914253... |
211 | LLY | 2017 | Revenue of Humalog, our injectable human insulin analog for the treatment of diabetes, increased 2 percent in the U.S., primarily driven by higher realized prices due to changes in estimates for rebates and discounts, which decreased revenue in 2016 and increased revenue in 2017. Revenue outside the U.S. increased 6 pe... | [-0.0157159473747015, -0.012536118738353252, 0.016762806102633476, -0.0010476753814145923, 0.020845549181103706, -0.0065788449719548225, -0.006680259481072426, -0.008270174264907837, -0.03669235482811928, -0.03692789748311043, 0.007504659704864025, 0.0020937148947268724, -0.020047321915626526, -0.017652634531259537, 0.... |
212 | LLY | 2017 | Revenue of Cialis, a treatment for erectile dysfunction and benign prostatic hyperplasia, decreased 8 percent in the U.S., driven by decreased demand partially offset by higher realized prices. Revenue outside the U.S. decreased 4 percent, driven by the decreased volume, partially offset by higher realized prices. We l... | [-0.017012277618050575, -0.01598004251718521, 0.022225717082619667, -0.009100654162466526, 0.013288391754031181, 0.02410726062953472, -0.004079941660165787, -0.006536399479955435, -0.02851059101521969, -0.02400273084640503, 0.006536399479955435, 0.04092354327440262, 0.011263120919466019, -0.000518567394465208, 0.001698... |
213 | LLY | 2017 | Revenue of Alimta, a treatment for various cancers, decreased 6 percent in the U.S., driven by decreased demand due to competitive pressure. Revenue outside the U.S. decreased 13 percent, driven by competitive pressure and the loss of exclusivity in several countries. We have faced and remain exposed to generic entry i... | [-0.012060687877237797, -0.022818222641944885, 0.018192026764154434, -0.021358691155910492, 0.009089497849345207, 0.02511177398264408, -0.007838469929993153, -0.005082299932837486, -0.020876523107290268, -0.012106298469007015, 0.017488323152065277, 0.026871031150221825, 0.017840174958109856, -0.01396980881690979, -0.00... |
214 | LLY | 2017 | Revenue of Trulicity, a treatment for type 2 diabetes,increased 118 percent in the U.S., driven by increased share of market for Trulicity and growth in the GLP-1 class. Revenue outside the U.S. increased 123 percent. | [0.006350188981741667, -0.029601499438285828, 0.018831370398402214, -0.005218212958425283, 0.03952101245522499, 0.0007029865519143641, -0.012072229757905006, -0.010848648846149445, -0.02284890227019787, -0.024209892377257347, 0.02190667949616909, 0.029575327411293983, -0.0057253120467066765, -0.012065686285495758, 0.00... |
215 | LLY | 2017 | Revenue of Forteo, an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid-induced osteoporosis in men and postmenopausal women, increased 25 percent in the U.S., driven by higher realized prices and increased volume, primarily due to wholesaler buying p... | [-0.01926194690167904, -0.03159646689891815, -0.006960477214306593, -0.02966630645096302, 0.007687592413276434, 0.0021945664193481207, -0.036990340799093246, -0.010014361701905727, -0.0077603040263056755, -0.01015978492796421, 0.024510398507118225, 0.01903720200061798, 0.004832012113183737, -0.0032720190938562155, 0.01... |
216 | LLY | 2017 | Revenue of Humulin, an injectable human insulin for the treatment of diabetes, increased 3 percent in the U.S., driven by higher realized prices. Revenue outside the U.S. decreased 11 percent, driven primarily by decreased volume and lower realized prices. | [-0.015555225312709808, -0.02873111516237259, 0.008813775144517422, 0.0013271830976009369, 0.02024993672966957, -0.011794340796768665, -0.007150798570364714, -0.011295448057353497, -0.03899040073156357, -0.02903812751173973, 0.006575153209269047, 0.018267156556248665, -0.00371291465125978, -0.021132592111825943, -0.001... |
217 | LLY | 2017 | Revenue of Cyramza, a treatment for various cancers, increased 3 percent in the U.S., driven by increased volume. Revenue outside the U.S. increased 39 percent, primarily due to strong volume growth in Japan, partially offset by lower realized prices and, to a lesser extent, the unfavorable impact of foreign exchange r... | [-0.0009387084282934666, -0.02726747840642929, 0.0008341351640410721, -0.018365679308772087, 0.015241553075611591, 0.0035849022679030895, -0.007875673472881317, -0.01187560148537159, -0.03775094822049141, -0.01824803464114666, 0.013254661113023758, 0.007993319071829319, 0.014117390848696232, -0.017712095752358437, -0.0... |
218 | LLY | 2017 | Revenue of Cymbalta, a product for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, chronic musculoskeletal pain, and the management of fibromyalgia, decreased 57 percent in the U.S., driven by reductions to the reserve for expected product returns, which i... | [-0.015540661290287971, -0.022903410717844963, 0.02824140526354313, -0.01876186393201351, -0.01019609346985817, 0.0020411908626556396, -0.01752597466111183, -0.016250640153884888, -0.005140777211636305, -0.026242943480610847, 0.018893342465162277, 0.02684774063527584, -0.005393871571868658, 0.010044894181191921, -0.010... |
219 | LLY | 2017 | Revenue of Erbitux, a treatment for various cancers, decreased 7 percent in the U.S. in 2017. The decrease was due to increased competition from immuno-oncology products. | [-0.01450339239090681, -0.015875333920121193, -0.00016649093595333397, -0.015156698413193226, 0.001590800005942583, -0.00047283017192967236, -0.014620986767113209, -0.01766539365053177, -0.008029130287468433, -0.006444863043725491, 0.01604519411921501, 0.012765598483383656, 0.011236862279474735, -0.011805238202214241, ... |
220 | LLY | 2017 | Revenue of Strattera, a treatment for attention-deficit hyperactivity disorder, decreased 47 percent in the U.S., driven by the loss of exclusivity in the second quarter of 2017, partially offset by higher realized prices. The entry of generic competition following the loss of effective patent protection has caused a r... | [-0.015326756983995438, 0.007087330799549818, 0.02401278167963028, -0.009281490929424763, 0.002521018497645855, 0.013721589930355549, -0.0007787164067849517, -0.023779774084687233, -0.01539148110896349, -0.012278233654797077, 0.012168202549219131, 0.024880090728402138, 0.0033041846472769976, 0.0044821701012551785, 0.00... |
221 | LLY | 2017 | Worldwide food animal revenue decreased 8 percent, primarily driven by market access and competitive pressure in the U.S. for Posilac® and Optaflexx®, respectively. Worldwide companion animal revenue increased 10 percent, driven by the inclusion of $216.7 million in revenue from the acquisition of BIVIVP, partially off... | [-0.011940385214984417, -0.02083502896130085, 0.0024814035277813673, -0.018786566331982613, -0.00900245737284422, 0.00023478995717596263, -0.014177522622048855, -0.016670718789100647, -0.015174801461398602, -0.022034458816051483, 0.008867690339684486, 0.007600877434015274, 7.870201079640538e-05, -0.012701820582151413, ... |
222 | LLY | 2017 | Gross margin as a percent of total revenue was 73.5 percent in 2017, an increase of 0.1 percentage points compared with 2016 primarily due to manufacturing efficiencies and higher realized prices, offset by the impact of foreign exchange rates on international inventories sold and product mix. | [-0.002110737841576338, -0.003999125678092241, -0.00641956552863121, -0.004440649412572384, -0.006098745856434107, -0.017368720844388008, -0.011066682636737823, -0.002215560059994459, -0.024331456050276756, -0.02960433065891266, 0.006727679166942835, 0.039438556879758835, -0.004253240302205086, -0.00511722918599844, 0.... |
223 | LLY | 2017 | Research and development expenses increased 1 percent to $5.28 billion in 2017. | [-0.0006819668924435973, -0.003237133612856269, -0.004935223143547773, -0.02053772658109665, -0.001961558358743787, -0.0041223252192139626, 0.0007767514325678349, -0.018468530848622322, -0.013391933403909206, -0.006130472756922245, 0.01204888429492712, 0.020743360742926598, 0.014188766479492188, -0.010037524625658989, ... |
224 | LLY | 2017 | Marketing, selling, and administrative expenses increased 2 percent to $6.59 billion in 2017, driven by increased marketing expenses for new products that were partially offset by decreased expenses related to late life-cycle products. | [-0.0007158758817240596, -0.0014078893000259995, -0.002074449323117733, -0.02200443483889103, -0.016811948269605637, -0.012624869123101234, -0.005685645621269941, 0.0023830714635550976, -0.009214118123054504, -0.02013361267745495, 0.021202653646469116, 0.02233532816171646, 0.011676731519401073, 0.006516061723232269, 0.... |
225 | LLY | 2017 | We recognized acquired IPR&D charges of $1.11 billion in 2017 resulting from business development activity, primarily related to the acquisition of CoLucid. In 2016, we recognized acquired IPR&D charges of $30.0 million associated with the agreement with AstraZeneca to co-develop MEDI1814. See Note 3 to the consolidate... | [-0.0003629956627264619, 0.005203077103942633, 0.013340194709599018, -0.03617091104388237, 0.012538179755210876, 0.006696831434965134, -0.0003043064789380878, 0.011321788653731346, 0.004320859909057617, -0.0019081290811300278, 0.015572472475469112, 0.016534890979528427, 0.004651691298931837, 0.010031879879534245, -0.00... |
226 | LLY | 2017 | We recognized asset impairment, restructuring, and other special charges of $1.67 billion in 2017. The charges are primarily associated with efforts to reduce our cost structure, including the U.S. voluntary early retirement program, asset impairments related to lower projected revenue for Posilac, and asset impairment... | [-0.020989583805203438, -0.006273627281188965, 0.02361992560327053, -0.028455499559640884, -0.005513086915016174, 0.019289162009954453, -0.00326965912245214, 0.013869067654013634, -0.0052141849882900715, -0.006635631434619427, 0.0030388401355594397, 0.02166709676384926, -0.012228425592184067, 0.013370896689593792, 0.00... |
227 | LLY | 2017 | Other—net, (income) expense was income of $52.4 million in 2017, compared with expense of $84.8 million in 2016. Other—net, (income) expense in 2016 included a $203.9 million charge related to the impact of the Venezuelan financial crisis, including the significant deterioration of the bolívar, partially offset by net ... | [-0.03655017167329788, -0.016196276992559433, 0.01295965351164341, -0.019314488396048546, -0.010387458838522434, -0.015841038897633553, 0.004611531738191843, -0.003008021041750908, 0.0038451359141618013, -0.012084712274372578, 0.008663889952003956, 0.031497880816459656, 0.003128078766167164, 0.0040885405614972115, 0.00... |
228 | LLY | 2017 | During 2017, we recorded income tax expense of $2.40 billion which included a provisional tax charge of $1.91 billion, despite earning $2.20 billion of income before income taxes. The provisional tax charge is a result of the 2017 Tax Act, including the Toll Tax. Refer to “Results of Operations - Executive Overview - O... | [-0.014847145415842533, -0.019369252026081085, -0.001291446853429079, -0.037797488272190094, -0.010651781223714352, -0.013278785161674023, -0.008541029877960682, -0.01594499871134758, -0.014598822221159935, -0.012579557485878468, 0.012422721832990646, 0.02020571008324623, 0.0011419624788686633, 0.00786794163286686, 0.0... |
229 | LLY | 2017 | (1) Operating expense consists of research and development and marketing, selling, and administrative expense. | [-0.004523754585534334, -0.0016495458548888564, -0.011215662583708763, -0.027867328375577927, -0.007579163648188114, -0.0015964355552569032, 0.006292017642408609, 0.002044749679043889, -0.007073052693158388, -0.014396036975085735, 0.015845637768507004, 0.03848940506577492, -0.0022603152319788933, 0.005892127752304077, ... |
230 | LLY | 2017 | Revenue and gross margin increased in 2016. The increase in operating expense in 2016 was due to an increase in research and development expense, partially offset by a decrease in marketing, selling, and administrative expense. Net income and EPS increased in 2016 as a higher gross margin and lower acquired IPR&D charg... | [-0.008994382806122303, -0.006929345428943634, -0.006008273456245661, -0.04046161100268364, -0.00271896505728364, -0.005945994984358549, 0.013937359675765038, 0.0006801509880460799, -0.010508743114769459, -0.018355881795287132, 0.026052242144942284, 0.01979812979698181, 0.02124037779867649, -0.007493133656680584, -0.00... |
231 | LLY | 2017 | Certain items affect the comparisons of our 2016 and 2015 results. The 2016 highlighted items are summarized in the "Results of Operations - Executive Overview" section. The 2015 highlighted items are summarized as follows: | [-0.024081449955701828, -0.002167594851925969, 0.014565179124474525, -0.05046266317367554, -0.01613800786435604, 0.003565296996384859, -0.02085649035871029, -0.0055115059949457645, -0.031800203025341034, -0.018636027351021767, -0.0022006374783813953, 0.015265682712197304, -0.018768198788166046, -0.003195219673216343, 0... |
232 | LLY | 2017 | •We recognized expense of $153.0 million (pretax), or $0.10 per share, related to the fair value adjustments to Novartis AH acquisition date inventory that was sold. | [-0.0003695525520015508, -0.012610170990228653, 0.014185631647706032, -0.011696014553308487, 0.002291874261572957, 0.0010235633235424757, -0.028578730300068855, -0.00446704775094986, 0.000940089812502265, 0.0054914215579628944, 0.015599007718265057, 0.022938191890716553, 0.009738033637404442, -0.004924125503748655, 0.0... |
233 | LLY | 2017 | •We recognized acquired IPR&D charges of $535.0 million (pretax), or $0.33 per share, related to upfront fees paid in connection with various collaboration agreements primarily with Pfizer, as well as the consideration paid to acquire the worldwide rights to Locemia Solutions' (Locemia) intranasal glucagon. | [0.009338969364762306, 0.0038801354821771383, 0.035996999591588974, -0.04423021525144577, 0.011570463888347149, 0.007613725028932095, -0.006497977767139673, -0.005911794491112232, -0.006101638078689575, -0.002517924876883626, 0.028083521872758865, 0.014028438366949558, 0.005505462642759085, -0.0007318967836908996, 0.00... |
234 | LLY | 2017 | •We recognized charges of $367.7 million (pretax), or $0.25 per share, related to severance costs, integration costs, and intangible asset impairments. | [0.0017455726629123092, -0.008106174878776073, 0.01630277745425701, -0.03350982815027237, -0.005254480522125959, 0.0038528551813215017, -0.010528338141739368, -0.003407177049666643, -0.008939399383962154, -0.009016908705234528, 0.006555989850312471, 0.056995127350091934, 0.015824804082512856, 0.000694353599101305, 0.00... |
235 | LLY | 2017 | •We recognized net charges of $152.7 million (pretax), or $0.09 per share, attributable to the debt extinguishment loss of $166.7 million from the purchase and redemption of certain fixed-rate notes, partially offset by net gains from non-hedging interest rate swaps and foreign currency transactions associated with the... | [-0.03358765318989754, -0.01283190306276083, 0.014586187899112701, -0.021222246810793877, -0.003129131393507123, -0.011603246442973614, -0.00643894774839282, -0.00127054238691926, -0.012555948458611965, -0.007187968119978905, 0.010387730784714222, 0.0451514795422554, -0.005660360679030418, 0.009868673048913479, 0.01113... |
236 | LLY | 2017 | Numbers may not add due to rounding. | [-0.008122851140797138, -0.008246813900768757, 0.028420191258192062, -0.0178376492112875, -0.017668016254901886, -0.003810236928984523, -0.03303945064544678, -0.02540592849254608, -0.01646753028035164, -0.02672385238111019, 0.008971019648015499, 0.025014465674757957, -0.021517399698495865, 0.003350268118083477, -0.0113... |
237 | LLY | 2017 | (1) U.S. revenue includes revenue in Puerto Rico. | [-0.002270389348268509, -0.026054497808218002, 0.00866758357733488, -0.010976782999932766, 0.016377851366996765, -0.022458096966147423, 0.003209916641935706, -0.0053557902574539185, 0.014864258468151093, -0.0334542840719223, 0.012102275155484676, 0.01859002560377121, 0.003389413235709071, -0.010905630886554718, -0.0095... |
238 | LLY | 2017 | Numbers may not add due to rounding. | [-0.008122851140797138, -0.008246813900768757, 0.028420191258192062, -0.0178376492112875, -0.017668016254901886, -0.003810236928984523, -0.03303945064544678, -0.02540592849254608, -0.01646753028035164, -0.02672385238111019, 0.008971019648015499, 0.025014465674757957, -0.021517399698495865, 0.003350268118083477, -0.0113... |
239 | LLY | 2017 | In the U.S., the volume increase in 2016 was driven by sales of several pharmaceutical products, including Trulicity, Humalog, Erbitux (due to the transfer of commercialization rights to us in the U.S. and Canada effective October 1, 2015), Taltz, and Jardiance, partially offset by decreased volume for Zyprexa. U.S. re... | [-0.0009160328772850335, -0.022938920184969902, 0.036787085235118866, -0.03442825749516487, 0.002488031517714262, 0.016140731051564217, -0.01571667194366455, -0.009302785620093346, -0.016511783003807068, -0.023707527667284012, 0.02806738018989563, 0.024953199550509453, -0.012841025367379189, -0.014378237538039684, -0.0... |
240 | LLY | 2017 | Outside the U.S., the volume increase in 2016 was driven by sales of several new pharmaceutical products, including Cyramza and Trulicity, partially offset by the losses of exclusivity for Cymbalta in Europe and Canada, Zyprexa in Japan, as well as Alimta in several countries. | [0.007750692777335644, -0.022289743646979332, 0.03019649162888527, -0.03303147479891777, -0.010045990347862244, 0.020456107333302498, -0.011021329089999199, -0.00671683344990015, -0.009031637571752071, -0.014148916117846966, 0.029468238353729248, 0.022016650065779686, -0.0056862253695726395, -0.009233207441866398, 0.00... |
241 | LLY | 2017 | Numbers may not add due to rounding. | [-0.008122851140797138, -0.008246813900768757, 0.028420191258192062, -0.0178376492112875, -0.017668016254901886, -0.003810236928984523, -0.03303945064544678, -0.02540592849254608, -0.01646753028035164, -0.02672385238111019, 0.008971019648015499, 0.025014465674757957, -0.021517399698495865, 0.003350268118083477, -0.0113... |
242 | LLY | 2017 | (1) U.S. revenue includes revenue in Puerto Rico. | [-0.0022463470231741667, -0.026069914922118187, 0.008713691495358944, -0.010964890010654926, 0.01632765866816044, -0.022434359416365623, 0.003200518898665905, -0.005417755339294672, 0.014839798212051392, -0.03356097266077995, 0.012135772034525871, 0.018604733049869537, 0.0034123773220926523, -0.010945483110845089, -0.0... |
243 | LLY | 2017 | (2) Trajenta revenue includes Jentadueto. | [-0.008748926222324371, -0.02048301510512829, 0.019256966188549995, 0.0005863712867721915, 0.02537388540804386, 0.008049278520047665, -0.03059791959822178, -0.026133501902222633, -0.006386782508343458, -0.02461426705121994, 0.019483517855405807, 0.031557437032461166, -0.002582032699137926, -0.0007662806310690939, 0.014... |
244 | LLY | 2017 | Revenue of Humalog decreased 5 percent in the U.S., driven by lower realized prices, partially offset by increased demand. Revenue outside the U.S. increased 1 percent, driven by increased volume and, to a lesser extent, higher realized prices, partially offset by the unfavorable impact of foreign exchange rates. | [-0.02249053120613098, -0.019764790311455727, 0.018966084346175194, -0.0023311423137784004, 0.017672942951321602, -0.0016750628128647804, -0.0008652642136439681, -0.009711244143545628, -0.0325821116566658, -0.04198908433318138, -0.0021378048695623875, 0.02746025286614895, -0.005774767138063908, -0.026496736332774162, -... |
245 | LLY | 2017 | Revenue of Cialis increased 17 percent in the U.S., driven by higher realized prices. Revenue outside the U.S. decreased 5 percent, driven by the unfavorable impact of foreign exchange rates and decreased volume, partially offset by higher realized prices. | [-0.006099000107496977, -0.013349715620279312, 0.02359425462782383, -0.007508419454097748, 0.012942478992044926, 0.004330067429691553, -0.01070904266089201, -0.0012312536127865314, -0.035938605666160583, -0.025146842002868652, -0.002333655022084713, 0.032553452998399734, 0.007966560311615467, -0.007788394577801228, 0.0... |
246 | LLY | 2017 | Revenue of Alimta decreased 5 percent in the U.S., driven by decreased demand due to competitive pressure. Revenue outside the U.S. decreased 11 percent, driven primarily by the loss of exclusivity in several countries. We faced exposure to generic entry in multiple countries that eroded revenue. | [-0.011911166831851006, -0.017164956778287888, 0.019160881638526917, -0.028638308867812157, 0.007294784765690565, 0.02706732228398323, -0.008672617375850677, -0.004500489681959152, -0.02022966742515564, -0.018104974180459976, 0.020178159698843956, 0.026449229568243027, 0.020564468577504158, -0.014357784762978554, -0.00... |
247 | LLY | 2017 | Revenue of Forteo increased 26 percent in the U.S., driven by higher realized prices. Revenue outside the U.S. decreased 1 percent, driven by lower realized prices, largely offset by increased volume and the favorable impact of foreign exchange rates. | [-0.0002519088448025286, -0.015932196751236916, -0.0026485060807317495, -0.03229499235749245, 0.0017983878497034311, -0.002898633945733309, -0.02380964159965515, -0.008270051330327988, -0.028698217123746872, -0.013753867708146572, 0.011721182614564896, 0.018756425008177757, 0.010157091543078423, -0.014526414684951305, ... |
248 | LLY | 2017 | Revenue of Humulin increased 13 percent in the U.S., driven by increased demand and, to a lesser extent, higher realized prices. The increase in realized prices resulted from a change in estimate of a government rebate in the first quarter of 2016. Revenue outside the U.S. decreased 7 percent, driven by the unfavorable... | [-0.01392404455691576, -0.02542983554303646, -0.005657438654452562, -0.005520616192370653, 0.01062122080475092, -0.015362268313765526, 0.004018754232674837, -0.014344057068228722, -0.03220094367861748, -0.03278641402721405, 0.003493738826364279, 0.01519680954515934, -0.01123851165175438, -0.021560631692409515, -0.00198... |
249 | LLY | 2017 | Revenue of Cymbalta was $269.3 million in the U.S. in 2016, compared to $144.6 million in 2015. U.S. revenue benefited from reductions to the Cymbalta reserve for expected product returns of approximately $175 million in 2016. Revenue outside the U.S. decreased 25 percent, driven by the loss of exclusivity. | [-0.006281276233494282, -0.01970471441745758, 0.04063379764556885, -0.024665966629981995, -0.008519578725099564, 0.0007401224575005472, -0.0011510358890518546, 0.0028823723550885916, -0.006644761189818382, 5.739237167290412e-05, 0.020049069076776505, 0.03645053133368492, -0.009814095683395863, -0.0016532191075384617, -... |
250 | LLY | 2017 | Revenue of Trulicity was $737.6 million in the U.S., driven by growth in the GLP-1 market and increased share of market for Trulicity. Revenue outside the U.S. was $187.9 million. | [0.015997495502233505, -0.019447680562734604, 0.022807413712143898, -0.010492702946066856, 0.033054597675800323, -0.006273653823882341, -0.01113880518823862, 0.00015526647621300071, -0.013115878216922283, -0.016695285215973854, 0.028790321201086044, 0.025391822680830956, -0.014937886968255043, -0.011746141128242016, -0... |
251 | LLY | 2017 | Revenue of Strattera increased 7 percent in the U.S., driven by higher realized prices, partially offset by decreased volume. Revenue outside the U.S. increased 13 percent, driven by increased volume and, to a lesser extent, the favorable impact of foreign exchange rates, partially offset by lower realized prices. | [-0.002433265559375286, -0.0077991727739572525, 0.013486335054039955, -0.01790120080113411, 0.010897212661802769, 0.006278779357671738, -0.0048887962475419044, -0.013893469236791134, -0.022595971822738647, -0.007366592530161142, 0.006768613122403622, 0.020407624542713165, -0.0036101392470300198, -0.002783146919682622, ... |
252 | LLY | 2017 | Revenue of Zyprexa, a treatment for schizophrenia, decreased 16 percent outside the U.S., driven primarily by decreased volumes in Japan due to the entry of generic competition in June 2016 following the loss of patent exclusivity. Zyprexa revenue in Japan was $332.3 million in 2016, compared with $415.9 million in 201... | [0.0032722288742661476, -0.011268130503594875, 0.03501608595252037, -0.00870218500494957, 0.012926924042403698, 0.013296264223754406, 0.006320909131318331, -0.011209813877940178, -0.00027275324100628495, -0.033823829144239426, 0.006285271141678095, 0.016574973240494728, 0.009797247126698494, -0.007568243891000748, -0.0... |
253 | LLY | 2017 | Revenue of Erbitux increased to $581.1 million in the U.S. in 2016, compared to $386.7 million in 2015. The increase was due to the transfer of commercialization rights to us in the U.S. and Canada which occurred on October 1, 2015. | [0.0003499604936223477, -0.02067558467388153, -0.007502506021410227, -0.045261017978191376, 0.008221037685871124, -0.003447009716182947, -0.004608959425240755, -0.017257705330848694, 0.0016636272193863988, -0.009088453836739063, 0.02235863171517849, -0.00106566003523767, -0.004926149267703295, -0.018371105194091797, -0... |
254 | LLY | 2017 | Revenue of animal health products in the U.S. increased 1 percent, primarily due to uptake of new companion animal products, partially offset by decreased revenue for food animal products. Animal health product revenue outside the U.S. decreased 3 percent driven by the unfavorable impact of foreign exchange rates. | [0.004923007916659117, -0.0037138480693101883, -0.001653798040933907, -0.013857356272637844, 0.008342563174664974, -0.012756956741213799, 0.004590329248458147, -0.02002471126616001, -0.02272452786564827, -0.019384944811463356, 9.896397386910394e-05, 0.0077283866703510284, 0.001577825634740293, -0.007395708002150059, -0... |
255 | LLY | 2017 | Gross margin as a percent of total revenue was 73.4 percent in 2016, a decrease of 1.4 percentage points compared with 2015 primarily due to a lower benefit from foreign exchange rates on international inventories sold. | [-0.0030690375715494156, -0.0027648136019706726, 0.0036979776341468096, -0.017263533547520638, -0.005359387956559658, -0.017339196056127548, -0.014665807597339153, -0.008612851612269878, -0.00580074917525053, -0.018486736342310905, 0.009539710357785225, 0.030794411897659302, 0.0038965903222560883, -0.004303273279219866... |
256 | LLY | 2017 | Research and development expense increased 9 percent to $5.24 billion in 2016, driven primarily by higher late-stage clinical development costs and, to a lesser extent, higher charges related to development milestone payments. | [0.005676127504557371, -0.011435727588832378, 0.004818929359316826, -0.04029793664813042, -0.004491460509598255, -0.005772441625595093, 0.009657122194766998, 0.0008628162904642522, -0.015602929517626762, 0.009650700725615025, 0.006298960652202368, 0.01785026490688324, 0.011320150457322598, -0.010530372150242329, 0.0012... |
257 | LLY | 2017 | Marketing, selling, and administrative expense decreased 1 percent to $6.45 billion in 2016, as reduced spending on late-life-cycle products was largely offset by expenses related to new products. | [-0.003393270308151841, -0.005067369434982538, 0.0020201869774609804, -0.026244724169373512, -0.015092647634446621, -0.010115422308444977, -0.005427944473922253, 0.006261774804443121, -0.005434383638203144, -0.018003005534410477, 0.017655307427048683, 0.03100946731865406, 0.012439844198524952, 0.0059011997655034065, -0... |
258 | LLY | 2017 | We recognized an acquired IPR&D charge of $30.0 million in 2016 associated with the agreement with AstraZeneca to co-develop MEDI1814. There were $535.0 million of acquired IPR&D charges in 2015 resulting from business development activity, primarily a collaboration with Pfizer and the acquisition of worldwide rights t... | [-0.003656578715890646, 0.005276496522128582, 0.025273410603404045, -0.04237329214811325, 0.008603714406490326, 0.015150602906942368, -0.0040800427086651325, 0.0008385260589420795, 0.0011006705462932587, -0.005353795830160379, 0.023001492023468018, 0.010546271689236164, -0.003187743481248617, 0.010499220341444016, -0.0... |
259 | LLY | 2017 | We recognized asset impairment, restructuring, and other special charges of $382.5 million in 2016. The charges are primarily associated with integration and severance costs related to the acquisition of Novartis AH, other global severance costs associated with actions taken to reduce cost structure, and asset impairme... | [-0.023770539090037346, -0.005523581989109516, 0.026317855343222618, -0.023110613226890564, -0.004447902087122202, 0.019758189097046852, -0.003269934095442295, 0.011568505316972733, -0.003962856251746416, -0.00735817663371563, -0.00020261794270481914, 0.020286129787564278, -0.0048669553361833096, 0.004431404173374176, ... |
260 | LLY | 2017 | Other-net, (income) expense was expense of $84.8 million in 2016, compared with income of $100.6 million in 2015. Other expense in 2016 included a $203.9 million charge related to the impact of the Venezuelan financial crisis, including the significant deterioration of the bolívar, partially offset by net gains of $101... | [-0.03736899420619011, -0.014069571159780025, 0.01359353307634592, -0.03258216381072998, -0.0018859704723581672, -0.00878025870770216, 0.0008330667042173445, -0.006489325314760208, -0.00012913360842503607, -0.0042612021788954735, 0.00314714084379375, 0.02520357444882393, 0.004545502830296755, 0.006115767639130354, -2.2... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.